Comparing the current results to its competitors, Kyntra Bio Inc reported Revenue increase in the 1 quarter 2026 by 36.47 % year on year. The sales growth was above Kyntra Bio Inc 's competitors' average revenue growth of 21.42 %, achieved in the same quarter.
Kyntra Bio Inc , slower than the average decrease reported by the company's competitors of -22.48 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -22.48 %
Kyntra Bio Inc 's Comment on Competition and Industry Peers
The company operates in a competitive environment for the development and commercialization of pharmaceutical product candidates, particularly in the prostate cancer market. Competitors include large pharmaceutical companies with established commercial organizations and greater resources, as well as extensive experience in clinical testing, regulatory approvals, patient recruitment, manufacturing, and commercialization. The company and its collaboration partner, Kyntra Bio, compete against these entities. Competition also extends to patient recruitment and enrollment in clinical trials, as well as access to third-party providers such as contract research organizations (CROs), clinical data management organizations, medical institutions, and clinical investigators, who may prioritize other companies with more extensive agreements and relationships.
Strong sales growth of 36.47 % in Overall company contributed to Kyntra Bio Inc increase in total revenue by 36.47 % Kyntra Bio Inc improved its market share in this segment, to approximately 0 %.
Wave Life Sciences Ltd is a biotechnology company focused on developing and commercializing nucleic acid therapies for rare genetic diseases. Their business model revolves around utilizing their proprietary chemistry platform to design and create custom-built, targeted medicines that can potentially address a wide range of genetic disorders. They aim to bring these therapies through preclinical and clinical development stages and ultimately deliver innovative treatments to patients in need.
Biovie Inc is a biotechnology company that aims to develop advanced therapeutic solutions for various diseases. They have a unique business model that focuses on research and development of innovative drugs, strategic partnerships and collaborations with other organizations, along with potential commercialization of their products to generate revenue. Their goal is to create groundbreaking medical treatments that improve the quality of life for patients.
Bristol Myers Squibb Company operates a research and development-driven business model, focusing on the discovery and delivery of innovative medicines for various diseases. It emphasizes collaboration with academic institutions, government entities, and other pharmaceutical firms to enhance its therapeutic portfolio and improve patient outcomes.
Sources:
Kyntra Bio Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Kyntra Bio Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
